Drug Database
PT

PT-007

✓ Approved

Pediatrix Therapeutics · 未知 · 未知

什么是 PT-007?

PT-007 是一种未知,由Pediatrix Therapeutics研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

公司Pediatrix Therapeutics
药物类别未知
给药途径Unknown
状态Approved

治疗适应症

PT-007 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersHereditary haemochromatosis✓ Approved

相关研究文献

PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-11-19

Temperature-Dependent Alloy-to-Oxide Transformation in Platinum-Group-Metal High-Entropy-Alloy Nanocrystals.

Lin Jui-Tai JT, Chang Chun-Wei CW, Lin Shang-Cheng SC, Hsu Yu-Chuan YC et al.

Herein, we unravel how temperature governs the oxidation kinetics and alloy-to-oxide phase transformation of platinum-group-metal high-entropy-alloy (HEA, PtPdIrRuRh) nanocrystals in air. By integrating synchrotron high-resolution powder X-ray diffraction (HRPXRD) with Rietveld refinement, scanning transmission electron microscopy (STEM), temperature-programmed oxidation (TPO), X-ray photoelectron spectroscopy (XPS), synchrotron X-ray absorption spectroscopy (XAS), and quantitative compositional analyses, we correlate oxidation-pathway fingerprints with the structural and compositional evolution from room temperature to 900°C. At 300°C, the nanocrystals preserve a single-phase face-centered-cubic (FCC) lattice, with only a thin amorphous oxide overlayer forming, indicating surface-limited oxidation. At 600°C, a rutile-type multicomponent oxide becomes the dominant crystalline phase, accompanied by clear elemental partitioning: Ru, Ir, and Rh are preferentially enriched in the oxygen-rich oxide regions, whereas Pt and Pd are preferentially concentrated in the oxygen-poor residual FCC metallic and/or PdO-related regions. At 900°C, this redistribution becomes more pronounced, producing Pt-rich FCC metallic domains that coexist with Pt-depleted, Rh/Ir/Ru-rich oxide regions. These results show that alloy-to-oxide transformation in compositionally complex nanocrystals couples crystal-structure evolution with elemental partitioning, rather than proceeding through a composition-invariant phase transition, providing a general framework for understanding the oxidative stability and phase segregation of multicomponent nanocrystals under high-temperature conditions.

PMID 43053529
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Early and mid-term outcomes after surgical repair of post-infarction ventricular septal rupture from the Netherlands Heart Registration: a nationwide analysis.

Ronco Daniele D, Matteucci Matteo M, Di Mauro Michele M, Kowalewski Mariusz M et al.

Ventricular septal rupture (VSR) is a rare, life-threatening complication of acute myocardial infarction. Large cohort data from multicentre studies are scarce and only recent evidence is accumulating about the current short- and long-term results of this condition. The early and mid-term outcomes after surgical VSR repair were analysed from the Netherlands Heart Registration database. All adults who underwent surgical VSR repair in the Netherlands from 1 January 2014 to 31 December 2019 were included. The primary outcomes were in-hospital and mid-term mortality. Secondary outcomes included post-operative complications, and predictors of early and overall mortality. Overall, 227 consecutive patients [68.7% males, median age 67.0 (59.0-74.0) years] underwent VSR repair in the 6-year period. Critical pre-operative status was present in 66.5% of patients and emergent/salvage surgery was required in 60.4% of subjects. In-hospital mortality was 39.2%. Post-discharge mortality occurred in 16.9% of hospital survivors at a median follow-up of 2.8 [0.9-4.5] years. Independent association with in-hospital mortality was found for older age (P = .001), higher body mass index (P = .021), emergent/salvage surgery (P = .007), higher pre-operative serum creatinine (P = .007), and intra-operative extracorporeal membrane oxygenation (P = .049). Independent association with overall mortality included older age (P = .003), emergent/salvage surgery (P = .002), and higher pre-operative creatinine (P = .002), while pre-operative left ventricular ejection fraction >50% was independently associated with better survival (P = .019). Logistic EuroSCORE I predicted in-hospital mortality more reliably than EuroSCORE II. Surgical VSR repair remains associated with frequent severe peri-operative complications and remarkable in-hospital mortality. However, mid-term follow-up for patients discharged from hospital shows excellent 5-year survival.

PMID 43053828
阅读全文 →
PubMedBMC cancer2026-11-19

Pulmonary embolism in lung cancer: a retrospective exploratory study.

Shang Junyi J, Wu Zhuhua Z, Jiang Miao M, Yuan Lin L et al.

Lung cancer is associated with a high risk of venous thromboembolism, and pulmonary embolism (PE) is a critical complication. The synchronous diagnosis of PE at the initial presentation of lung cancer presents diagnostic challenges and affects management. The predictive factors for this dual diagnosis remain poorly defined. A retrospective comparative study was conducted on 251 newly diagnosed lung cancer patients, including 79 with concurrent PE (observation group) and 172 without PE (control group). Demographic, clinical, laboratory, and tumor - related data were collected. Statistical analysis included univariate and multivariate logistic regression to seek independent risk factors and ROC curve analysis to evaluate their potential predictive performance. Univariate analysis revealed significant differences in multiple variables, including pericardial/pleural effusion, smoking index, hematologic parameters, coagulation markers, D - dimer, liver enzymes, albumin, and tumor markers (CEA, CA125, CA199) (P < 0.05). Multivariate logistic regression analysis indicated that smoking index, hemoglobin, PT, direct bilirubin, albumin, and CEA may be independent risk factors for synchronous pulmonary embolism in lung cancer patients. The combination of the six independent risk factors also demonstrated significant predictive potential (AUC = 0.857, sensitivity 79.1%, specificity 79.7%). Lung cancer patients presenting with synchronous PE exhibit a distinct clinical phenotype. The smoking index, hemoglobin, PT, direct bilirubin, albumin, and CEA may be independent predictive factors. D - dimer is a well diagnostic marker. These findings suggest a practical framework to help guide clinical suspicion and encourage targeted diagnostic evaluation for PE at the initial diagnosis of lung cancer, contributing to improved early intervention and patient outcomes.

PMID 43052863
阅读全文 →
PubMedThrombosis journal2026-11-19

Concentration-dependent and platform-specific interference of argatroban and bivalirudin in routine coagulation assays.

Yan Jinghai J, Chen Wanjun W, Chen Weidong W, Yang Yongqiang Y et al.

Argatroban and bivalirudin may interfere with routine coagulation and antithrombin assays through direct thrombin inhibition. However, the magnitude of interference differs across analytical platforms owing to distinct assay principles and reagent formulations. This study aimed to characterize the specific impacts of argatroban and bivalirudin on results of routine coagulation and antithrombin tests on three widely utilized coagulation analytical platforms. Pooled normal human plasma was spiked with clinically relevant concentrations of argatroban (0-2.0 µg/mL) or bivalirudin (0-20 mg/L). Antithrombin (AT) activity, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and Clauss fibrinogen (FIB) were measured simultaneously on all three analytical platforms. Corresponding antigen concentrations of AT and ClaussFIB were quantified via immunoassays to discriminate analytical interference from genuine biological alterations. On Stago and Sysmex platforms, AT activity increased concentration‑dependently with both DTIs, whereas no significant change was observed on Werfen. Fibrinogen levels decreased markedly with argatroban only on Werfen, and with bivalirudin across all three platforms. PT, APTT, and TT were prolonged dose‑dependently on all platforms, though TT frequently exceeded the detection limit at low DTI concentrations. Inter‑platform agreement assessed by intraclass correlation coefficients was poor to moderate for most parameters. Antigen levels remained unchanged, confirming that the observed discrepancies were due to analytical interference. Argatroban and bivalirudin produce significant platform-dependent interference in coagulation testing, particularly in thrombin-based fibrinogen and AT activity assays. Such interference may lead to falsely decreased fibrinogen activity and falsely elevated AT activity. Platform-specific validation and confirmatory testing are essential for accurate interpretation of coagulation results during direct thrombin inhibitor therapy.

PMID 43053079
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Myocardial performance during exercise in hypertrophic cardiomyopathy; pressure volume loops and haemodynamic forces analysis.

Modesti Pietro Amedeo PA, Toncelli Loira L, Falconi Edoardo E, Pedrizzetti Gianni G et al.

Developments in cardiac fluid dynamics imaging have recently increased interest in haemodynamic force (HDF) analysis, which expresses the forces exchanged between blood and surrounding tissues and corresponds to the global value of the intraventricular pressure gradients. The study was designed to investigate the pattern of HDF during exercise and their relationship with the mechanical characteristics of the left ventricle in patients with hypertrophic cardiomyopathy (HCM), who meet the morphological criteria for HCM despite normal conventional index of systolic and diastolic function. Fifty-four participants (27 with non-obstructive HCM and 27 healthy controls) underwent transthoracic echocardiography at incremental levels of exercise intensity. A novel non-invasive analysis of intraventricular HDF and the study of non-invasive pressure-volume (PV) loops were performed. Differences between groups were investigated using mixed model analysis. HCM patients generate lower longitudinal HDF during exercise compared with controls (P = .007 for group × intensity interaction), despite similar values in ejection fraction, strain, and conventional echocardiographic parameters. The findings suggest that only HDF analysis may allow to detect early cardiac dysfunction over the entire cardiac cycle, in systole, and diastole. When selected phases of diastole were studied, an impaired early diastolic relaxation was documented in the absence of any alteration at PV loops analysis. HDF may have the potential to detect early functional impairment in HCM. Prospective studies are needed to define its clinical relevance, to understand future evolution, and whether there are thresholds for risk stratification or how this relates to clinical outcomes.

PMID 43053816
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Win ratio analysis for the 1-year composite endpoint: a substudy of the LANDMARK trial.

Tobe Akihiro A, van Royen Niels N, Amat-Santos Ignacio J IJ, Hudec Martin M et al.

Conventional time-to-first event analyses for composite endpoints consider only the first event, whereas win ratio analyses account for event severity and recurrence. We performed a win ratio analysis of the 1-year composite endpoint in the LANDMARK trial, a multicentre, non-inferiority study that randomized patients with severe native aortic valve stenosis to receive either the Myval transcatheter heart valve (THV) series (n = 384) or contemporary THVs (n = 384), consisting of the Sapien and Evolut series (n = 192 each). The 1-year composite endpoint included the following components, ranked in hierarchical order: all-cause death, disabling stroke, non-disabling stroke, and procedure- or valve-related hospitalization. For death and stroke events, wins or losses were determined according to the time-to-first-event principle. For procedure- or valve-related hospitalizations, the total number of events was compared. Win ratio analysis was also conducted for an extended composite endpoint that also included quality-of-life outcomes. Among 147 456 (384 × 384) unmatched patient pairs, the win ratio for the primary composite endpoint was 1.02 (95% CI: 0.68-1.51; P = .94), with 17 870 (12.1%) wins for the Myval group and 17 599 (11.9%) for the contemporary group. For the extended composite endpoint, the win ratio was 1.13 (95% CI: 0.82-1.55; P = .45), with 27 007 (18.3%) wins for the Myval group and 23 920 (16.2%) for the contemporary group. Comparisons between the Myval and Sapien groups, and between the Myval and Evolut groups, were also not statistically significant. Win ratio analysis did not demonstrate a significant difference between Myval and contemporary THVs, consistent with the primary time-to-first event analysis of the LANDMARK trial.

PMID 43053854
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多PT-007